Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 Update by the GEMICOMED-SEIMC/REIPI.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Garcia-Vidal, C
  • Alastruey-Izquierdo, A
  • Aguilar-Guisado, M
  • Carratala, J
  • Castro, C
  • Fernandez-Ruiz, M
  • Aguado, JM
  • Fortun, J
  • Garnacho-Montero, J
  • Gavalda, J
  • Gudiol, C
  • Guinea, J
  • Gomez-Lopez, A
  • Muñoz P
  • Rovira, M
  • Ruiz-Camps, I
  • Cuenca-Estrella, M

Grupos

Abstract

Aspergillus infection is a significant cause of morbi-mortality in an at-risk population. The Study Group of Fungal Infections (GEMICOMED) from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) has reviewed announcements made in invasive aspergillosis management. We have organized our recommendations in such a way as to provide a guide in resolving different clinical situations concerning the entire spectrum of invasive diseases caused by Aspergillus in various populations. Diagnostic approach, treatment and preventions strategies are outlined. It is not our aim that these guidelines supplant clinical judgment with respect to specific patients; however, it is our objective to perform a comprehensive summary of quality of care evidence for invasive aspergillosis management in different settings.

Datos de la publicación

ISSN/ISSNe:
0213-005X, 1578-1852

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA  EDICIONES DOYMA S A

Tipo:
Article
Páginas:
535-541
PubMed:
29960829
Factor de Impacto:
0,317 SCImago ℠
Cuartil:
Q3 SCImago ℠

Citas Recibidas en Web of Science: 60

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Aspergillosis, Aspergilosis, Isavuconazol, Isavuconazole, Manejo clínico, Monitorización de noveles, Therapeutic drug monitoring, Tratamiento, Treatment, Voriconazol, Voriconazole

Cita

Compartir